World-class
Scientific Advisory

Work with Richmond Pharmacology and trust your experience will be personal and truly strategic.

Dr T.J Von Oertzen - Consultant Neurologist and Epileptologist (MD., F.R.C.P.)

Dr. von Oertzen studied medicine at Rheinische-Friedrich-Wilhelm University, Germany and completed his final year at University College of London in 1995. He was supervising consultant in Europe's largest centre for presurgical evaluation in epilepsy, Department of Epileptology, at the University of Bonn where he gained major experience in all aspects of blackouts, epilepsy, non epileptic attack disorders and other conditions. Dr. von Oertzen is fully trained in Neurophysiology, particularly in EEG (electroencephalogram recording of brainwaves) of both surface and intracranial recordings.

Dr. von Oertzen has been appointed as the lead clinician for the epilepsy service at the Atkinson Morley Neuroscience Centre, St George's Hospital, since 2004. At present, he is holding specialist clinics for first fits and blackouts, complex cases and people with drug refractory epilepsy including pre-surgical assessment. He holds an Honorary Senior Lecturer post at St George's University of London is also honorary Consultant Neurologist at Kingston Hospital.

Dr. von Oertzen has presented clinical and research data on national and international conferences. He has frequently published in medical journals and contributed to definite books about epilepsy. He is involved in raising awareness for epilepsy and providing continuous medical education for medical professionals.

Back to experts

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Do we still need challenge trials with COVID-19?

April 21, 2021
Nir Eyal and colleagues suggested that the initiation of COVID-19 challenge trials in response to the UK governments’ call in 2020 remained relevant and important despite the development of approved vaccines and the introduction of an aggressive, UK-wide vaccination policy.
Read more

Novel rate-controlled fentanyl patch shows promise in phase I clinical trial

April 1, 2021
Our expertise in ethnic differences and access to over 12,000 first generation Japanese volunteers accelerated our ability to provide robust clinical trial data to support future applications of new chronic pain medicines to the Japanese drug market.
Read more

A new era for UK-Japanese scientific relations

March 23, 2021
Dr Taubel uses his experience of conducting more than 60 Japanese bridging studies to explain why the deal is of strategic importance to the UK and highlights the scientific requirements for conducting successful Japanese trials abroad
Read more